 |
|
|
| |
Virological non-inferiority and lower weight gain with DTG/3TC versus BIC/FTC/TAF: 96-week final results from the PASO-DOBLE (GeSIDA 11720) randomised, multicentre, open-label, non-inferiority trial
|
| |
| |
EACS 2025 Oct 15-18 Paris
HIV Lancet publication, Ryan et al.
Downlaod PDF here
|
| |
|
|
|
|
|
